Navigation Links
Aspirin May Boost Breast Cancer Survival
Date:2/16/2010

Risk of death, recurrence halved for those who took it, study finds

TUESDAY, Feb. 16 (HealthDay News) -- A new study of more than 4,000 women who were diagnosed with breast cancer shows that taking aspirin appears to significantly increase survival and reduce the risk of recurrence.

"Women who took aspirin were 50 percent less likely to die from breast cancer [during the study follow-up period] than those who did not take it," said study author Dr. Michelle Holmes, an associate professor of medicine and epidemiology at Harvard Medical School and School of Public Health, in Boston.

The study is published online Feb. 16 in the Journal of Clinical Oncology.

The 50 percent reduction is the overall finding when comparing to users to nonusers, she said. "Statistically, the women who took it more days per week had a higher risk reduction," Holmes noted. For instance, those who took it six to seven days a week had a 64 percent reduction in risk of death during the follow-up. For some reason, those who took aspirin two to five days a week had an even greater risk reduction, 71 percent, Holmes found.

But the most important finding, in her view, was the overall 50 percent reduction. She didn't have access to doses, just number of days a week the women took aspirin, she noted.

Aspirin use also reduced the risk of recurrence of the cancer in similar fashion.

"It is a surprisingly strong effect," Holmes said, though she acknowledged that it was an observational study and does not establish definitive cause and effect.

Exactly how aspirin confers a risk reduction is not known, Holmes said. But the new research is in line with some previous studies. "We're appreciating more and more that cancer is an inflammatory disease, and aspirin is an anti-inflammatory," she said.

Aspirin might lower estrogens in the blood or might prevent early spread of cancer, the researchers speculated.

For the study, Holmes and her colleagues evaluated aspirin use among women at least one year after having been diagnosed with breast cancer. The women, diagnosed with stage 1, 2 or 3 breast cancer between 1976 and 2002, were all participants in the Nurses' Health Study.

During the follow-up, which went until a woman's death or June 2006, 341 women died of breast cancer and 400 had distant recurrences, or metastatic disease.

Aspirin would never be a substitute for recommended cancer treatments, Holmes said. And aspirin does have negative effects in some. "It can cause bleeding of the GI tract," she noted.

More study is needed, Holmes said, but for now, "if a woman has breast cancer and is taking aspirin for other reasons [such as arthritis or pain], she may take some comfort in knowing she might be doing something to help prevent her breast cancer from recurring."

"This is the largest study of aspirin use and breast cancer recurrence and survival to date," said Eric Jacobs, director of pharmacoepidemiology for the American Cancer Society. Previous research has produced mixed findings, he noted.

"While the results from this study are exciting, there are some important caveats," he said. Like Holmes, he noted that the findings do not prove cause and effect.

"As noted by the study authors, it is possible that survival results could have been influenced by women with recurrent breast cancer being advised to stop taking aspirin during chemotherapy, resulting in an overestimate of any benefit of aspirin use," Jacobs said.

Both Holmes and Jacobs agreed that it's premature to suggest that breast cancer survivors take aspirin with an aim of reducing breast cancer recurrence or death from the disease. Women should talk to their doctor about what's best for them, they said.

More information

The American Cancer Society has more about breast cancer.



SOURCES: Michelle Holmes, M.D., associate professor, medicine and epidemiology, Harvard Medical School and School of Public Health, and associate physician, Brigham & Women's Hospital, Boston; Eric Jacobs, Ph.D., director, pharmacoepidemiology, American Cancer Society, Atlanta; Feb. 16, 2010, Journal of Clinical Oncology


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
2. AUDIO from Medialink and Bayer: Is Your Pain Reliever Undermining Your Aspirin Therapy?
3. AUDIO from Medialink and Bayer: Lifesaving Benefits of Low-Dose Aspirin Therapy Maintained with Naproxen Sodium
4. New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen
5. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
6. Aspirin Resistance Boosts Heart Risks in Cardiac Patients
7. Regular, long-term aspirin use reduces risk of colorectal cancer
8. Many stroke, heart attack patients may not benefit from aspirin
9. Women are treated less frequently than men with statins, aspirin and beta-blockers
10. Drugs like aspirin could reduce breast cancer and help existing sufferers
11. Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Marne, Michigan (PRWEB) , ... January 17, 2017 , ... January is National Stalking ... those who choose to lurk in the corners and commit the crime of stalking, a ... drug use and addiction, an often overlooked factor in stalking and other crimes. , “Stalking: ...
(Date:1/17/2017)... Illinois (PRWEB) , ... January 17, 2017 , ... For ... Breast Cancer Symposium (SABCS) or those who desire a more intimate review and analysis ... Breast Cancer – Bench to Bedside—is being offered by Imedex on February 4, 2017 ...
(Date:1/17/2017)... ... , ... Kevin Harrington (one of the original Sharks from mega-hit reality series ... topic of Beauty and Personal Care. , Everyone makes New Year’s ... commit to these changes than beginning with personal care and beauty products? AsSeenOnTV.pro will ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... A ... named winners of the fourth Cradle to Cradle Product Design Challenge , the ... fourth in a series of six circular design challenges scheduled to run through early ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... enero de 2017  Hoy, en el Foro Económico ... iniciativa global para avanzar el acceso a la prevención ... de renta baja y baja-media (LICs y LMICs). ... crisis, particularmente en países de renta baja y media, ... las muertes relacionadas con NCD. El objetivo de Access ...
(Date:1/18/2017)... -- With an annual growth ranging from 6% to 10%, South East Asia,s ... Expo, March 22-24, 2017) serves the industry by fostering the regional discourse - ... Investment Forum ASEAN -- India ... content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology: